CT1812 Meets Primary End Point in Phase 2 SHIMMER Study for Dementia with Lewy Bodies

The phase 2 SHIMMER study showed CT1812, an investigational therapy for dementia with Lewy bodies (DLB), met its primary endpoint of safety and tolerability, with improvements in behavioral, functional, cognitive, and movement measures. CT1812 demonstrated a slowing of decline across cognitive measures and a reduction in caregiver distress. Detailed data will be presented at the 2025 International Lewy Body Dementia Conference.